Barry Callebaut has halted manufacturing operations at its Weize chocolate plant in Belgium as a precautionary measure while conducting its root cause analysis and risk assessment after detecting salmonella in a production lot.
The company identified lecithin as the source of the contamination.
All chocolate products manufactured at the facility since June 25 have been placed on hold.
After the analysis, the lines will be cleaned and sanitized before production can resume.
Barry Callebaut, which informed the Belgian food authorities (FAVV) about the incident, said that their robust food safety programs allowed them to identify lecithin as the source of the contamination quickly.
The company added that they are reaching out to all customers who may have received impacted products.
The news comes after Ferrero temporarily suspended production at its Arlon facility in Belgium after the site was linked to a salmonella outbreak.


Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 



